Peroxisome proliferator-activated receptor gamma (PPARg) is one of a subfamily of PPARs encoded by independent genes. Three human PPARs, designated PPARa, PPARg, and PPARd, have been identified. [3] [4] [5] Recent studies suggest that PPARg ligands have the ability to lower plasma glucose and triglyceride levels in insulin-resistant animal models.
Peroxisome proliferator-activated receptor gamma (PPARg) is one of a subfamily of PPARs encoded by independent genes. Three human PPARs, designated PPARa, PPARg, and PPARd, have been identified. [3] [4] [5] Recent studies suggest that PPARg ligands have the ability to lower plasma glucose and triglyceride levels in insulin-resistant animal models. 6 ) Some glucose and lipid lowering agents, which have transcriptional activity at PPARg, are currently used for clinical treatment of type 2 diabetes. [7] [8] [9] In a previous paper, we showed (E)-4-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}-4-phenylbutyric acid (TAK-559) (1), a novel oxyiminoalkanoic acid derivative, had strong functional activity at PPARg (Chart 1).
2) TAK-559 also exhibits marked glucose and lipid lowering activities in insulin-resistant animal models, KKA y mice and Wistar fatty rats, 2, [10] [11] [12] [13] and is under clinical trials. Metabolites M-I, M-II, M-III and M-IV were found during preclinical and clinical studies on TAK-559 (1), and their proposed structures are shown in Chart 1. To confirm the structures and to study the biological properties of the metabolites, compounds 2-5 (Charts 2-4) were synthesized and their biological activities were evaluated by both in vitro and in vivo experiments. Analytical high-performance liquid chromatography (HPLC) and mass spectroscopy (MS) of isolated metabolites (M-I, M-II, M-III, M-IV) and synthesized compounds (2) (3) (4) (5) were shown to be identical respectively (data not shown). Transactivation activities of compounds 1-5 for human PPAR subtypes were examined using in vitro experiments, and the glucose and lipid lowering effects of the compounds were evaluated in Wistar fatty rats using in vivo experiments. The results are described below.
Chemistry
Compounds 2 and 3 were synthesized from commercially available 6a and 6b, respectively (Chart 2). Friedel-Crafts acylation of 6a-b gave aryl ketones 7a-b, of which the methoxy groups were converted into hydroxy groups using boron tribromide to yield 8a-b. Reactions of 8a-b with 9 2) gave aldoximes, which were hydrolyzed to afford 2 and 3.
Compound 4 was prepared following the procedure described in Chart 3. The hydroxy group of compound 10 14) was protected using chloromethyl methyl ether to give 11. Lithiation at the 5-position of the oxazole 11 with n-butyllithium, followed by treatment with N,N-dimethylformamide, yielded aldehyde 12. Reduction of 12 gave the corresponding alcohol, which was protected using tert-butylchlorodiphenylsilane to yield 13. Selective removal of the methoxymethyl group of 13 was achieved using bromotrimethylsilane to give alcohol 14. Compound 14 was reacted with methanesulfonyl chloride, then coupled with 15 2) to provide 16. Removal of the tert-butyldiphenylsilyl group of 16 and subsequent hydrolysis of the ester group gave the desired compound 4.
Chart 4 shows the synthesis of 5. Chloromethyloxazole 17 15) was reacted with methyl 4-hydroxybenzoate under basic conditions to yield 18. Hydrolysis of 18 gave 5 in good yield.
Results and Discussion
To investigate the effect of TAK-559 (1) and its metabolites (2-5) on the full-length PPAR subtypes, COS-1 cells were transiently transfected with PPAR expression plasmid, human retinoid X receptor alpha (hRXRa) expression plasmid and reporter construct containing four copies of the rat acetyl-CoA oxidase peroxisome proliferator response ele-ment (PPRE), and then transfected cells were treated with TAK-559 and its metabolites.
TAK-559 (1) and its metabolites (2-5) activated hPPARg1 in a dose-dependent manner (data not shown). The EC 50 values for 1, 2, 3, 4 and 5 were 31 nM, 16) 130 nM, 210 nM, 200 nM and 970 nM, respectively (Table 1) . Thus, TAK-559 is the most potent activator of hPPARg1 among these compounds.
In a transient cotransfection assay for hPPARa, TAK-559 (1) and its metabolites (2-4) activated hPPARa in a dosedependent manner (data not shown), while compound 5 failed to activate it. The EC 50 values for 1, 2, 3, and 4 were 67 nM, 16) 240 nM, 540 nM and 580 nM, respectively ( Table 1 ), indicating that TAK-559 (1) is significantly more potent than its metabolites as an activator of hPPARa.
To examine whether TAK-559 (1) and its metabolites (2- a) Full-length hPPARg1 (or hPPARa)-hRXRa expression plasmids were cotransfected into COS-1 cells with PPAR responsive luciferase reporter plasmid, and cells were cultured in the presence of 1, 3, 10, 30, 100, 300, 1000, 3000, and 10000 nM of each compound or vehicle (0.1% DMSO) alone for 48 h. The cell extracts were then assayed for luciferase activity. Transactivation activity is represented as EC 50 . Data are the mean (nϭ5). b) From reference 16. c) Not determined because of poor activity.
plays the key role for in vivo glucose and lipid lowering activities, rather than its metabolites (2) (3) (4) (5) . However, it is well known that the in vivo activities of compounds can be significantly different from their in vitro activities. So, to understand the role of metabolites (2-5) on glucose and lipid lowering activities, the in vivo activities of these metabolites were measured in Wistar fatty rats after intraperitoneal administration. Table 2 shows the effects of TAK-559 (1) and its metabolites (2-5) on the ED 25 values of plasma glucose and triglyceride lowering activities in Wistar fatty rats. TAK-559 (1) showed potent plasma glucose and triglyceride lowering activities, decreasing the plasma triglyceride level by 30% even at the lowest dose (0.1 mg/kg). Hence, it was necessary to estimate the ED 25 value for the plasma triglyceride lowering effect of TAK-559 (1) by extrapolation. Compounds 2 and 4 had less potent effects on plasma glucose and triglyceride levels than TAK-559 (1). The plasma glucose levels in 3-injected rats and the plasma triglyceride levels in 5-injected rats showed relatively weak effects compared with those in 1-injected rats.
In conclusion, TAK-559 (1) is a more potent activator of both hPPARg1 and hPPARa than its metabolites (2-5). TAK-559 (1) also showed potent plasma glucose and triglyceride lowering activities, while its metabolites (2-5) showed comparatively weak activities, in Wistar fatty rats after intraperitoneal administration. These results indicate that TAK-559 itself plays a key role for treatment of diabetes, rather than its metabolites (2-5).
Experimental Biological Procedures. (a)
In Vitro Transient Cotransfection Assay COS-1 cells were seeded at 5ϫ10 6 cells in a 150 cm 2 tissue culture flask, and cultured in 5% CO 2 at 37°C overnight. Transfections were performed with LipofectAMINE (GIBCO BRL, U.S.A.) according to the instructions of the manufacturer. Briefly, the transfection mixture contained 125 ml of LipofectAMINE, 100 ml of LipofectAMINE Plus, 2.5 mg of each expression plasmid pMCMVneo-hPPARg (pMCMVneo-hPPARd or pMCMVneo-hPPARa), pMCMVneo-hRXRa, 5 mg of reporter plasmid pGL3-PPREϫ4-tkluc-neo and 5 mg of pRL-tk (Promega, U.S.A.). Cells were incubated in 25 ml of transfection mixture for 3 h in 5% CO 2 at 37°C. After adding 25 ml of Dulbecco's modified eagle medium (DMEM, Nikken Bio Medical Lab., Japan) containing 0.1% fatty acid-free bovine serum albumin (BSA), the cells were then incubated for 24 h in 5% CO 2 at 37°C. After transfection, cells were detached by treating with trypsin-EDTA (GIBCO BRL, U.S.A.) centrifuged and then suspended in DMEM medium containing 0.1% fatty acid free-BSA. The suspended cells were added in an OPAQUE PLATE (white 96 well plate, COSTAR, U.S.A.) at the density of 8.8ϫ10
3 cells/well in 80 ml of DMEM medium containing 0.1% fatty acid free-BSA and 20 ml of test compounds, and then cultured in 5% CO 2 at 37°C for 48 h. After removing the medium, 40 ml of PICAGENE-LT7.5 (Wako Pure Chemical Ind., Ltd., Japan) was added. After stirring, luciferase activities were determined in a microplate-based luminescence reader (Amersham Pharmacia, U.K.).
(b) In Vivo Male Wistar fatty rats 11) were bred in Takeda Chemical Industries, Ltd. and used at the age of 27-weeks. Throughout the study, they were housed in metal mesh cages and fed a commercial diet CE-2 (Clea, Japan) and water ad libitum. They were divided into 16 groups (5 rats in each group) based on plasma glucose and triglyceride, and they were intraperitoneally injected with TAK-559 (1) and its metabolites (2-5) for 7 d. Compounds (1) (2) (3) (4) (5) were suspended in 0.5% methylcellulose saline solution. TAK-559 was injected into 3 groups of rats at the doses of 0.1, 0.3 and 1.0 mg/kg/d, and each metabolite was injected into 3 groups of rats at the doses of 0.3, 1.0 and 3.0 mg/kg/d. Before and after the 7-d treatment, blood was withdrawn from the tail vein, and the plasma glucose and triglyceride levels were enzymatically measured using an Autoanalyzer 7070 (Hitachi, Japan). The change (%) from the initial level of plasma glucose and triglyceride after the 7-d treatment was calculated in each rat. The degrees of variation (% control value) in the plasma parameters after treatment were also estimated from the relative ratio of the change (%) in each rat to the average of the change (%) in the control group, and the ED 25 values for the glucose and triglyceride lowering activities of TAK-559 and its metabolites were calculated by least-squares linear regression analysis using % control values.
Chemical Methods Melting points were recorded on a Yanagimoto micro melting point apparatus and are uncorrected. Elemental analyses (C, H, N) were carried out in the Takeda Analytical Research Laboratories, and all values are within Ϯ0.4% of calculated values, unless otherwise noted. IR spectra were recorded on a JASCO IR-810. 1 H-NMR spectra were recorded on a Varian Gemini-200 spectrometer in CDCl 3 or DMSO-d 6 using tetramethylsilane as an internal standard. Chemical shifts are expressed as d (ppm) values for protons relative to the internal standard. All compounds exhibited 1 H-NMR spectra and analytical data consistent with their proposed structures. Column chromatography was performed using Merck Silica Gel 60 (0.063-0.200 mm). The following abbreviations are used: sϭsinglet, dϭdoublet, tϭtriplet, qϭquartet, quinϭquintet, sextϭsextet, septϭseptet, mϭmultiplet, brϭbroad, dec.ϭdecomposed.
Ethyl 4-(4-Methoxyphenyl)-4-oxobutanoate (7a)
Ethyl succinyl chloride (48.8 g, 297 mmol) was added dropwise to a suspension of aluminum chloride (43.6 g, 327 mmol) in dichloromethane (300 ml) at 0°C, and the mixture was stirred at 0°C for 15 min. To this was added anisole (32.2 ml, 297 mmol) dropwise at 0°C. The reaction mixture was stirred at room temperature for 15 h, then poured onto ice (500 g). After stirring at room temperature for 1 h, the organic layer was separated, washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with ethyl acetate-hexane (1 : 5, v/v) and recrystallized from ethyl acetate-hexane to give 7a (47.1 g, 67%) as colorless crystals. mp 49-50°C. Ethyl 4-(4-Hydroxyphenyl)-4-oxobutanoate (8a) Boron tribromide (2.40 ml, 25.4 mmol) was added to a stirred mixture of ethyl 4-(4-methoxyphenyl)-4-oxobutanoate (7a, 2.00 g, 8.46 mmol) in dichloromethane (15 ml) at 0°C, and the mixture was stirred at 0°C for 1 h and at room temperature for an additional 15 h. The reaction was quenched by addition of water and extracted with ethyl acetate. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo to leave an oil. The oil was dissolved in ethanol (20 ml), then sulfuric acid (0.2 ml) was added. The mixture was refluxed for 2.5 h. After cooling to room temperature, it was diluted with ethyl acetate, washed with water, brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with ethyl acetate-hexane (1 : 2, v/v) to give 8a (1.16 g, 62%) as crystals. Recrystallization of 8a from ethyl acetate-hexane gave colorless crystals. mp 111-112°C. 1 2) (9, 1.54 g, 4.95 mmol), ethyl 4-(4-hydroxyphenyl)-4-oxobutanoate (8a, 1.00 g, 4.50 mmol), acetic acid (0.773 ml, 13.5 mmol), sodium acetate (738 mg, 9.00 mmol), and ethanol (30 ml) was refluxed for 48 h, then diluted with ethyl acetate, washed with water, brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with ethyl acetate-hexane (1 : 2, v/v) to leave an oil. The oil was dissolved in tetrahydrofuran (20 ml), water (10 ml) and ethanol (10 ml), then lithium hydroxide monohydrate (755 mg, 18.0 mmol) was added. The reaction mixture was stirred at room temperature for 4 h, then made acidic by addition of 1 M hydrochloric acid (18.5 ml) and extracted with ethyl acetate. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. 4-(Methoxymethoxymethyl)-2-phenyl-1,3-oxazole (11) Sodium hydride (60% in oil, 12.5 g, 314 mmol) was added to a cold (0°C) stirred solution of (2-phenyl-1,3-oxazol-4-yl)methanol 14) (10, 50.0 g, 285 mmol) in tetrahydrofuran (700 ml), and the mixture was stirred at 0°C for 10 min and at room temperature for an additional 1 h. The mixture was cooled to 0°C, then chloromethyl methyl ether (26.0 ml, 342 mmol) was added dropwise. The reaction mixture was stirred at 0°C for 10 min and at room temperature for an additional 3 h. The mixture was poured into water and extracted with ethyl acetate. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with diethyl ether-hexane (1 : 1, v/v) to give 11 (61.4 g, 98%) as a pale yellow oil. 4-(Methoxymethoxymethyl)-2-phenyl-1,3-oxazole-5-carbaldehyde (12) n-Butyllithium (1.6 M in hexane, 193 ml, 308 mmol) was added dropwise to a cold (Ϫ78°C) stirred solution of 4-(methoxymethoxymethyl)-2-phenyl-1,3-oxazole (11, 61.4 g, 280 mmol) in diethyl ether (1000 ml), and the mixture was stirred at Ϫ78°C for 1 h. N,N-Dimethylformamide (65.0 ml, 840 mmol) was added dropwise to the mixture, then the resultant mixture was allowed to warm to room temperature and stirred at that temperature for 1 h. The mixture was poured into water and extracted with diethyl ether. The organic extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with diethyl ether-hexane (1 : 1, v/v) to give 12 (55.9 g, 81%) as a pale yellow oil. phenyl-1,3-oxazole (13) Sodium borohydride (3.90 g, 103 mmol ) was added to a cold (0°C) stirred solution of 4-(methoxymethoxymethyl)-2-phenyl-1,3-oxazole-5-carbaldehyde (12, 50.9 g, 206 mmol) in tetrahydrofuran (300 ml) and methanol (30 ml). The mixture was stirred at 0°C for 0.5 h, then poured into water and extracted with ethyl acetate. The organic extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo to leave an oil. The oil was dissolved in N,N-dimethylformamide (500 ml). The solution was cooled to 0°C, then imidazole (29.5 g, 433 mmol) was added, followed by addition of tert-butylchlorodiphenylsilane (67.9 g, 247 mmol) dropwise. The reaction mixture was stirred at room temperature for 1 h. The solvent was evaporated in vacuo. The residue was diluted with ethyl acetate, washed with 1 M hydrochloric acid, water, brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with ethyl acetate-hexane (1 : 8, v/v) to give 13 (80.1 g, 66%) as a colorless oil. (14, 3 .00 g, 6.70 mmol) in ethyl acetate (30 ml). The mixture was stirred at 0°C for 2 h, then poured into water and extracted with ethyl acetate. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo to leave an oil. The oil was dissolved in N,N-dimethylformamide (15 ml). Methyl (E)-4-(4-hydroxybenzyloxyimino)-4-phenylbutanoate 2) (15, 2.00 g, 6.38 mmol) was added to the solution, followed by addition of potassium carbonate (1.76 g, 12.8 mmol). The reaction mixture was stirred at 50°C for 1 h, then poured into water and extracted with ethyl acetate. The organic extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with ethyl acetate-hexane (1 : 6, v/v) 64 mmol) in tetrahydrofuran (30 ml). The mixture was stirred at room temperature for 1 h. The reaction mixture was poured into water and extracted with ethyl acetate. The organic extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo to leave an oil. The oil was dissolved in tetrahydrofuran (20 ml), water (10 ml) and methanol (10 ml), then lithium hydroxide monohydrate (584 mg, 13.9 mmol) was added. The reaction mixture was stirred at room temperature for 1 h, then made acidic by addition of 1 M hydrochloric acid (14.0 ml) and extracted with ethyl acetate. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was crystallized from ethyl acetate-hexane to give 4 (1.89 g, 84%) as colorless crystals. mp 139-141°C. 1 
5-(tert-Butyldiphenylsilyloxymethyl)-4-(methoxymethoxymethyl)-2-

